Anal Cancer: Current and Future Methodology

Overview

Journal Cancer Invest

Specialty Oncology

Date 2006 Aug 31

PMID 16939964

Citations 19

Authors

Cathy Eng

Affiliations

Soon will be listed here.

Abstract

Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat. For although it is one of the few malignancies that may be cured with chemoradiation alone, the use of combined modality therapy may result in significant treatment-related morbidity. Novel approaches currently are underway in this select patient population and will be addressed for the purposes of this manuscript.

Citing Articles

Immunotherapy in Anal Cancer.

Dhawan N, Afzal M, Amin M Curr Oncol. 2023; 30(5):4538-4550.

PMID: 37232801 PMC: 10217754. DOI: 10.3390/curroncol30050343.

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).

Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S ESMO Open. 2022; 7(4):100529.

PMID: 35816951 PMC: 9463376. DOI: 10.1016/j.esmoop.2022.100529.

Evolution of the Role of Radiotherapy for Anal Cancer.

Dee E, Byrne J, Wo J Cancers (Basel). 2021; 13(6).

PMID: 33801992 PMC: 8001637. DOI: 10.3390/cancers13061208.

A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer.

Eng C, Fakih M, Amin M, Morris V, Hochster H, Boland P Oncotarget. 2020; 11(15):1334-1343.

PMID: 32341753 PMC: 7170499. DOI: 10.18632/oncotarget.27536.

Anal cancer and immunotherapy-are we there yet?.

Bian J, Almhanna K Transl Gastroenterol Hepatol. 2019; 4:57.

PMID: 31559338 PMC: 6737437. DOI: 10.21037/tgh.2019.08.02.